Companion Diagnostics pipelines

We are developing companion diagnostic to measure AIMP2-DX2 expression to make patient selection conveniently for clinical testing. Quantitative real-time PCR method is available for research use, and developing a Immunohistochemistry method.


Also, we are working on other components of ARS pathways as targets for the following companion diagnostic, Lysyl-tRNA synthetase(KRS) highly expressed in metastatic squamous cell lung carcinoma(SCLC) and adenocarcinoma, Glysyl-tRNA synthetase(GRS) highly expressed in renal carcinoma, lung and liver cancer.